STOCK TITAN

VYNE Therapeutics Inc - VYNE STOCK NEWS

Welcome to our dedicated news page for VYNE Therapeutics (Ticker: VYNE), a resource for investors and traders seeking the latest updates and insights on VYNE Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VYNE Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VYNE Therapeutics's position in the market.

Rhea-AI Summary
VYNE Therapeutics Inc. announced its participation in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. David Domzalski, President, and CEO, along with Dr. Iain Stuart, CSO, will engage in a fireside chat on March 28, 2024, discussing innovative therapies for immuno-inflammatory conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.85%
Tags
conferences
-
Rhea-AI Summary
VYNE Therapeutics Inc. had a transformative year in 2023, achieving clinical proof-of-concept for VYN201 in vitiligo and securing funding. The company ended 2023 with $93.3 million in cash, providing runway through 2025. Plans include a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
earnings
-
Rhea-AI Summary
VYNE Therapeutics announces positive safety and efficacy data for VYN201 in vitiligo treatment, with plans to advance to Phase 2b trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences clinical trial
Rhea-AI Summary
VYNE Therapeutics Inc. announced that its CEO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference. The company is developing therapies for immuno-inflammatory conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
conferences
-
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced new biomarker data from the Phase 1b trial for VYN201, a BET inhibitor, showing positive effects on key biomarkers related to vitiligo. The program is on track for Phase 2b initiation in Q2, following previously announced positive clinical results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
clinical trial
-
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. Dr. Borowski brings expertise in immunology and extensive experience in the biopharmaceutical industry, which will provide valuable perspectives as VYNE seeks to execute on its strategic objectives of developing novel immuno-inflammatory therapies through its InhiBET™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
management
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced an $88.2 million capital raise, extending funding for BET inhibitor programs through 2025. Positive Phase 1b results for VYN201 in vitiligo and on track for VYN202 IND submission by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
earnings
-
Rhea-AI Summary
VYNE Therapeutics Inc. will host a virtual R&D Day event to present VYN201 Phase 1b trial results and VYN202 preclinical data, along with its clinical development plans. The event will feature a presentation from Dr. Amit Pandya, former President of the Global Vitiligo Foundation, and a live Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
conferences
-
Rhea-AI Summary
VYNE Therapeutics Inc. has successfully closed a private placement financing, raising $88.2 million. The company sold 10,652,543 shares of common stock at a purchase price of $2.245 per share and issued pre-funded warrants to certain investors. The PIPE was priced to meet Nasdaq listing rules. VYNE plans to use the funds to support its BET inhibitor programs until the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
Rhea-AI Summary
VYNE Therapeutics announced positive preclinical data for its oral small molecule BD2-selective BET inhibitor, VYN202, in models of psoriasis and rheumatoid arthritis. VYN202 demonstrated significant inhibition of key inflammatory cytokines and showed efficacy comparable to another inhibitor. The company plans to initiate Phase 1a and Phase 1b trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.39%
Tags
none
VYNE Therapeutics Inc

Nasdaq:VYNE

VYNE Rankings

VYNE Stock Data

43.28M
10.16M
8.7%
60.8%
0.09%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Bridgewater

About VYNE

vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.